𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P159 Study on clinical and biological characteristics in chronic lymphocytic leukemia

✍ Scribed by T. Raposa; M. Bodnár; J.P. Dombi; Z. Gasztonyi; H. Aryan; J.L. Iványi; É. Marton; A. Palaczki; S. Petz; K. Szabó; E. Valasinyószky; A. Noszek; L. István

Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
62 KB
Volume
21
Category
Article
ISSN
0268-960X

No coin nor oath required. For personal study only.

✦ Synopsis

immunmodulant therapy was begun. We started steroid, cyclosporine and thalidomide therapy. The control abdominal and pelvic CT showed small residual tumor on the bladder. Repeated surgery was done, residual was taken out. At this time histological examination showed transient type between plasma cell and vascular variant. Now almost 3 years after onset of the disease with low dose steroid, cyclosporine and thalidomide therapy our patient does not have any symptoms or complaints. Conclusion: Castleman disease can be successfully treated with immunmodulant therapy.

📜 SIMILAR VOLUMES

Clinical, biological, and immunophenotyp
Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization
✍ Maria Dolores Tabernero; Jesus F. San Miguel; Juan Luis Garcia; Maria Garcia-Isi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 653 KB

## Abstract The clinical, biological, and immunophenotypical characteristics of B‐cell chronic lymphocytic leukemia (B‐CLL) patients with trisomy 12 detected by fluorescence in situ hybridization (FISH) using a chromosome 12 alpha‐centromeric probe (D12Z3) were analyzed in the present study. From a

BAFF and APRIL expression in B-cell chro
BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features
✍ Agnieszka Bojarska-Junak; Iwona Hus; Sylwia Chocholska; Ewa Wąsik-Szczepanek; Ma 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 571 KB

B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are involved in normal B cell survival and differentiation. We analyzed BAFF and APRIL plasma levels in patients with B-cell chronic lymphocytic leukemia (B-CLL). We also tested intracellular BAFF and APRIL expression in B-C

Release and clinical significance of sol
Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia
✍ B.D. Hock; L.J. Fernyhough; S.M. Gough; A. Steinkasserer; A.G. Cox; J.L. McKenzi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 488 KB

Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival. Culture of CLL cells with solid phase